Alzinova AB (SE:ALZ)

:ALZ

ALZ

Alzinova AB

RESEARCH TOOLSreports

Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr75.31M

Enterprise Valuekr34.37M

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding154,961,400

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetVery low debt-to-equity (~0.7%) provides structural financial flexibility for a clinical-stage biotech. This reduces near-term solvency risk, preserves optionality to raise capital or partner without immediate distress, and lengthens runway relative to highly levered peers.

Focused Lead Program (ALZ-101 Vaccine)A concentrated R&D focus on a disease-modifying Alzheimer’s vaccine (ALZ-101) creates a clear scientific and commercial thesis. Specialization can build technical depth, attract partners or grant funding, and create a differentiated pipeline asset if clinical proof-of-concept is achieved.

Multiple Potential Funding PathwaysThe company can pursue licensing, research grants, equity raises, and collaboration deals. These diversified, structural funding channels reduce reliance on a single cash source and support continued R&D investment until a partnering or clinical milestone converts programs into non-dilutive income.

Bears Say

Collapsed Revenue BaseTop-line revenue has effectively collapsed to zero, reflecting absence of commercial products or recurring contract income. Over the medium term this forces reliance on external financing and prevents operational self-sufficiency until licensing or product sales materialize.

Sustained Negative Cash FlowPersistent negative operating and free cash flow (TTM OCF ~ -23.9m; FCF ~ -38.3m) is a durable drain on resources. Continued burn increases the probability of future equity raises, diluting shareholders and creating operational constraints if funding windows narrow.

Large Ongoing Losses And Funding RiskSizable recurring net losses (TTM ~26.5m) create structural pressure on equity and returns. Without near-term revenue or a major partnership, losses magnify dilution risk and can erode investor optionality, limiting the firm’s ability to sustain long development timelines.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr75.31M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on May 13, 2026. The company reported -kr0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.056.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 154,961,400 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.